Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 4,101–4,200 of 4,628
Zhu, D., Zhang, J., Guo, P., Tao, S., Zeng, M., Zheng, X., & Feng, W. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4889003
Autoimmune interstitial lung disease
Herrán, M., Galindo, J. L., Chaves, J. J., Carrillo-Bayona, J. A., Polo, F. C., Rojas, M., & Anaya, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00007-2
Clinical Trials in Lung Transplantation
Kotecha, S., Ivulich, S., & Snell, G. I. (2023) · Organ and tissue transplantation · doi:10.1007/978-3-319-20788-9_50-1
Ragaee, S. M., Shamsy, A. M. A. E., Shweel, M., et al. (2024) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-024-01333-9
Automatic diagnostic support for diagnosis of pulmonary fibrosisPreprint
Pal, R., Barney, A. M., Sgalla, G., et al. (2024) · medRxiv · doi:10.1101/2024.08.14.24312012
Self-citationTRP channels in respiratory disorders
Bonvini, S. J., Wortley, M. A., & Belvisi, M. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18653-0.00030-7
Huang, J., Su, L., Wu, D., & Yuan, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4820805/v1
CREPT is required for pulmonary fibrosis induced by bleomycinPreprint
Wang, J., Sheng, J., Liu, S., Li, J., Chu, J., Wang, M., Wang, Y., Ren, F., Cao, C., Wang, X., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4805438/v1
3. Advances in Interstitial Pneumonia and Pulmonary Fibrosis
Takahashi, H. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1513
Zhang, S., Zhou, M., Shao, C., et al. (2024) · medRxiv · doi:10.1101/2024.09.18.24313787
Editorial of utility of the Global Lung Function Initiative (GLI) for ILD
Kishaba, T. (2024) · Thorax · doi:10.1136/thorax-2024-222356
İdiopatik Pulmoner Fibroziste Mevcut Durum ve Yeni Tedavi Yaklaşımları
Uçar, S. N., Elma, Y., Altınsoy, B., ERDEM, A. T., & Can, E. Y. (2024) · Medical Journal of Western Black Sea · doi:10.29058/mjwbs.1514437 · Cited by 1
Reyes-Cartes, F. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2024.05.004 · Cited by 2
LAPTM4B Alleviates Pulmonary Fibrosis by Enhancing NEDD4L-Mediated TGF-β Signaling SuppressionPreprint
Xu, K., Pan, X., Lian, H., Wang, Y., Wan, R., Li, Z., Pan, X., Li, Y., Yang, J., Rosas, I. O., et al. (2024) · eLife · doi:10.7554/elife.101412
Marega, M., Mejdoubi‐Charef, N., Wiegard, D., Khan, M. M., Bartkuhn, M., Gambs, L., Procida‐Kowalski, T., Wilhelm, J., Vásquez‐Pacheco, E., Noori, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618798
da Silva, R. K. P., Moreira, W. D. C., Higashi, P., & da Luz, L. D. P. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n10-149
Clinical Trials in Lung Transplantation
Kotecha, S., Ivulich, S., & Snell, G. I. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-030-36123-5_50
Larson‐Casey, J. L., VU-TICAR, N. N., Craver, J., Migliaccio, C. T., Holian, A., Kendall, R. L., Albright, J. M., & Venosa, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00170-4
Diffuse parenchymal lung disease
Paramothayan, D. S. (2019) · doi:10.1002/9781394322152.ch7
Anchoring Patient Voices to Shape the Future of Patient-reported Outcomes
Grant-Orser, A., & Guler, S. A. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202410-1028ed
Heart and lung transplantation
Doi, A., Marasco, S., Patel, H. C., Paraskeva, M. A., & McGiffin, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22148-4.00002-2
Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis
O’Mahony, A. T., Waldron, M., Henry, P. J., Shet, S. S., O’Regan, P. W., Bennett, D. M., Ryan, D. J., Maher, M. M., & Henry, M. T. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.106759
栗, 萱. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123077
Zhang, S., Zhou, M., Shao, C., Zhao, Y., Liu, M., Ni, L., Bao, Z., Zhang, Q., Zhang, T., Luo, Q., et al. (2024) · eLife · doi:10.7554/elife.102451.1
State of the ART: Drug Screening Reveals Artesunate as a Promising Anti-Fibrosis Therapy
Qiao, Y., Liang, J., & Jiang, D. (2024) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2024.10023
Molekulare Diagnostik der interstitiellen Lungenerkrankungen
Jonigk, D. D., Verleden, S. E., & Länger, F. P. (2024) · Springer eBooks · doi:10.1007/978-3-662-67073-6_36
(2000) · Time to knit · doi:10.1016/s1155-195x(20)61247-6
Type I Error Control of an Adaptive Endpoint Selection Procedure
Hu, N., Yung, G., & Mackey, H. M. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2455173 · Cited by 1
Klampfleitner, S., Fertl, A., Prinz, O., Doerfler-Schalm, M., Munker, D., & Henke, M. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102168
“Nintedanib has been approved for the treatment of IPF in many countries, including Europe and the USA [16,17].”
Zhang, S., Zhou, M., Shao, C., Zhao, Y., Liu, M., Ni, L., Bao, Z., Zhang, Q., Zhang, T., Luo, Q., et al. (2025) · eLife · doi:10.7554/elife.102451.2
Koga, Y., Satoh, T., Yamagata, R., Ishii, Y., Kada, W., Hisada, T., & Dobashi, K. (2025) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/j.nimb.2025.165634
Herrmann, A., & Parr, D. G. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-263966 · Cited by 1
Mycophenolate Mofetil Inhibits Ferroptosis by Boosting Autophagy to Prevent Pulmonary FibrosisPreprint
Liu, W., Liu, B., Li, H., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5159480
4. Idiopathic Pulmonary Fibrosis (IPF) -Up-to-Date-
Suda, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.508
Kelly, C. A., & Shaikh, M. M. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-0103
Opolot, E. E., Goshevski, F., Chaudhary, R., Kilgore, J. A., Williams, N. S., von Recum, H. A., & Desai, A. B. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03729-8
Pediatric Pulmonology 2024 Year in Review: Rare and Diffuse Lung Disease
Cheng, P. C., Liptzin, D. R., Garagozlo, K., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71096
Les traitements antifibrosants : où en sommes-nous 10 ans après ?
Hindré, R., & Uzunhan, Y. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.04.002
Chang, A., Sia, J. T., Casper, G. E., Wood, S. R., Markham, L., Westhoff, L. L., Saxton, A. J., Snow, G. L., Ry, P. M. V., & Raghu, G. (2025) · European Respiratory Journal · doi:10.1183/13993003.02317-2024
Self-citationTiming of lung transplant evaluation: considerations, barriers and alternatives
van der Ploeg, E. A., Hylkema, T. H., & Gan, C. T. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001176
Therapeutic effect of nintedanib in orbital fibroblasts in patients with Graves’ orbitopathy
Park, H. Y., Choi, S. H., Ko, J., & Yoon, J. S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2491554
Rebuttal From Drs Marinescu and Ryerson
Marinescu, D.-C., & Ryerson, C. J. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.12.008
Imaging of Diffuse Lung Diseases
Mura, R., Gallone, V. I., Roberti, C., Ledda, R. E., & Sverzellati, N. (2025) · Medical radiology · doi:10.1007/174_2025_575
The role of complex rehabilitation methods in the treatment of patients with COVID-19 pneumonia
Kostenko, A. A., Koneva, E. S., Zhumanova, E. N., et al. (2025) · Fizioterapevt (Physiotherapist) · doi:10.33920/med-14-2502-03
The Future of Precision Medicine in Interstitial Lung Disease
Adams, T. N., Patel, C., & Gulati, M. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_11
Big Data: Pearls and Pitfalls for Precision Medicine in Interstitial Lung Disease
Kaul, B., Collard, H. R., & Petersen, L. A. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_10
Self-citationBorghetti, P., Angelillo, R. M. D. A., Facheris, G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5239531
Kronborg-White, S., Jensen, J., Bendstrup, E., & Prior, T. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099664
Effectiveness Of Antifibrotic Treatment in Real-World Patients with Progressive Pulmonary FibrosisPreprint
Niitsu, T., Fukushima, K., Komukai, S., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5269510
Andresen, B. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103610
Yan, L., Li, J.-H., Zhang, A., Li, H., Pang, B., Meng, D.-Y., Fu, Q., Du, L.-J., & Su, Y. (2025) · Hereditas · doi:10.1186/s41065-025-00464-x
Parikh, M., Soni, A., & Gandhi, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22300-6.00019-x
Sonaiya, S., Jianu, A., Jianu, N., et al. (2025) · JMIR Research Protocols · doi:10.2196/73219
“Several clinical trials have demonstrated the safety and efficacy of antifibrotic agents in the treatment of ILD [12-14].”
Matson, S. M. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001190 · Cited by 1
Battista, M. D., Romei, C., Tavanti, L. M., Uggenti, V., Mitolo, S., Airò, E., Pistelli, F., Chimera, D., Carrozzi, L., Neri, E., et al. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105934 · Cited by 3
Matama, G., Azuma, K., Sekine, A., Matsuo, N., Okudela, K., Murotani, K., Kawahara, A., Tominaga, M., Zaizen, Y., Murata, D., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.012
Idiopathic pulmonary fibrosis in a patient with rheumatoid arthritis
Dobrianskyi, D. V., Tahiieva, N., Khranovska, M. S., et al. (2025) · Infusion & Chemotherapy · doi:10.32902/2663-0338-2025-2-45-49
Idiopathic pulmonary fibrosis in a patient with rheumatoid arthritis
Dobrianskyi, D. V., Tahiieva, N., Khranovska, M. S., et al. (2025) · Infusion & Chemotherapy · doi:10.32902/2663-0338-8-2025-2-45-49
Conti, M., Casara, A., Turato, G., Baraldo, S., Tinè, M., Semenzato, U., Cocconcelli, E., Biondini, D., Damin, M., Saetta, M. P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541645
The Changing Landscape of Lung Transplantation
Sadeleer, L. D., Godinas, L., Dupont, L., Ceulemans, L. J., Vos, R., & Bos, S. (2025) · Respiratory The American Medical Journal · doi:10.33590/respiramj/zkbr4615 · Cited by 2
Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease
Thévenin, R., Gillibert, A., Dognon, N., Drucbert, M., Lagache, L., Salaün, M., Cuvelier, A., Girault, C., & Artaud-Macari, É. (2025) · ERJ Open Research · doi:10.1183/23120541.00053-2025 · Cited by 1
Lee, J. H., Jang, J. H., Kim, S. Y., Park, M. S., Chung, M. P., Yoo, H., Jeong, S. H., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e212 · Cited by 1
Rosas, I. O., McDowell-Sanchez, A. K., Sanchez, S., Cala-García, J., Cohen, A. R. W., Echartea, M. E. R., Ochsner, S. A., Kraushaar, D. C., Celada, L. J., Sun, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.09.663937
Noroozi, H., & Pakzad, R. (2025) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x373765250710105821
Mycophenolate mofetil inhibits ferroptosis by boosting autophagy to prevent pulmonary fibrosis
Liu, W., Liu, B., Lv, C., Li, H., Wang, Y., Song, X., & Chen, M. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110553
Navigating the Alphabet Soup of Interstitial Lung Diseases ( ILD ): The Role of Pharmacists
Martirosov, A. L., Abdalla, M., Fleischman, M. E., Foster, B., Gonzales, J. P., Lipari, M., Malesker, M. A., Smith, Z., Wilken, L. A., & Williams, D. M. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70089
E., M., MD, G. M. G., MD, F. G. J., Hernández Silva, S. M. D., Robles Díaz, M. T. N. J., Soto Acosta, C. Y., & Landa Chávez, T. L. (2025) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2025.17.00620
(2025) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-24.1.29
Derseh, H. B., Davies, A., Young, A., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03803-w
Xia, D., Liu, X., Yang, Q., Li, J., Li, L., You, Y., Wang, J., Fang, W., & Yang, H. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70788
Sharma, P., Banerjee, S., Sanjan, G., et al. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1043
Ein neues Kapitel in der Therapie der Lungenfibrose
Krauss, E. (2025) · Pneumo News · doi:10.1007/s15033-025-4201-4
Iammarino, M., Alonso‐Pérez, J., Stojkovic, T., Pegoraro, E., Lowes, L. P., Díaz‐Manera, J., Alonso‐Pérez, J., Borland, H., Bruno, C., Cárdenas, L., et al. (2025) · Neuromuscular Disorders · doi:10.1016/j.nmd.2025.106212
Pulmonary Disease in the Older Adult
Guidot, D. M., Tighe, R. M., & Schmader, K. E. (2025) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.07.011
Küçük, S., Başyiğit, İ., Barış, S. A., & Boyacı, H. (2025) · Sakarya Medical Journal · doi:10.31832/smj.1605511
THOMAS, C. A., Chandel, A., Zineddin, M. A., Tang, C., Kim, H. C., Khangoora, V. S., King, C., Shlobin, O. A., & Nathan, S. D. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03897-2
Fibrose pulmonaire idiopathique
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)87782-2
Hedgehog signalling: on the way to curing idiopathic pulmonary fibrosis
Spagnolo, P., & Khor, Y. H. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00284-x
Igarashi‐Sugimoto, A., Tsujino, I., Shima, H., Nakamura, J., Nakaya, T., Sato, T., Watanabe, T., Ohira, H., Takamura, K., Otsuka, N., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108395 · Cited by 2
Oh, J. H., Park, M. S., Chung, M. P., Jeong, S. H., Song, J. W., Choi, S. M., Kim, Y. H., Park, S., Jegal, Y., Yoon, H., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679011 · Cited by 1
“Moreover, the introduction of antifibrotic therapies, such as pirfenidone and nintedanib, has led to a paradigm shift in the management of patients with IPF, prompting increased interest in dynamic prognostic indicators that reflect treatment responses and disease activity over time (16, 17).”
Uzair, A., Sohail, H., Sajawal, M., Bhatti, N. I., Waseem, M., Saleem, A., Ishaq, A., Toor, Z., Ahmad, O., & Giri, B. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004001 · Cited by 1
Micallef, C. M., Belhassen, M., Fourrier, J.-M., Nolin, M., Bornier, N., Jouneau, S., Kreuter, M., Samara, K. D., & Cottin, V. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003153
Self-citationCampisi, M., Cannella, L., Liviero, F., Tamiazzo, F., Balestro, E., Spagnolo, P., & Pavanello, S. (2026) · npj Aging · doi:10.1038/s41514-026-00434-1
Healthcare utilisation preceding the diagnosis of interstitial lung disease
Prior, T. S., Vestergaard, C. H., Kronborg-White, S. B., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00700-2025
Giangreco, G., Ramsden, Z., Rullan, A., Hooper, S., Novo, D., Leitão-Castro, J., Chakravarty, P., Milan, M., Mohammadi, H., Llop, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.23.684281 · Cited by 1
Gu, J.-M., Wang, S., Zhang, S., Xiao, S.-Y., Chenchen, & Han, G.-L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157501
Tsubokawa, N., Mimae, T., Mimura, T., Kagimoto, A., Kamigaichi, A., Miyata, Y., & Okada, M. (2025) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivaf260
Chen, G., Jiang, S., Kong, L., Yang, T., Sun, X., Xu, T., Li, F., Xie, Q., & Zhao, H. (2025) · International Journal of Radiation Research · doi:10.61882/ijrr.23.3.34
Sarcopenia in idiopathic pulmonary fibrosis: an updated systematic review and meta-analysis
Zeng, J., Liu, J., He, L., Zhu, J., He, J., Jiang, J., Chen, Z., Zhu, X., He, J., Yang, J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1681237 · Cited by 2
Wuyts, W. A., Bonella, F., Ishii, H., Lee, J. S., Renzoni, E. A., Hadl, S., Krzykalla, J., Stowasser, S., Engel, M., & Molina‐Molina, M. (2025) · ERJ Open Research · doi:10.1183/23120541.00973-2025 · Cited by 1
Self-citationExtracellular Remodeling, Tissue Fibrosis, and Clinical Translation
Fromes, Y. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70055
Pirfenidone treatment improves ischemic muscle function in mice with chronic kidney disease
Balestrieri, N. P., Dong, G., & RYAN, T. E. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00402-5
Singh, R. K., Pradhan, A. K., Roy, D., Arya, M., Chakravarti, R., Dutta, D., Kundu, A., Bhaduri, S., Singh, P., Kazi, T. A., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108519
Song, Y., Hudson, K. J., Ye, Z., Hawley, L., Pandey, B., Zarzoso, J., Rogowski, J., Sun, Y., Rees, W. A., & Xin, Y. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1621
“17,41 Overall, the safety profile of fipaxalparant when administered alone and co-administered with pirfenidone or nintedanib support its use in future clinical trials.”
Tsuda, H., Tanino, R., Okimoto, T., Ueno, S., Tanimoto, T., Tsubata, Y., Ishikawa, N., & Isobe, T. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108520 · Cited by 2
Ohteru, Y., Kakugawa, T., Kakugawa, M., Hirano, T., & Matsunaga, K. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.11.005 · Cited by 1
Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast
Moir, H., & Jinks, J. (2025) · EMJ Respiratory · doi:10.33590/emjrespir/nuyd2874
Nonspecific Interstitial Pneumonitis
Hasan, A. (2025) · Springer eBooks · doi:10.1007/978-981-96-7810-5_53
Hou, P., Wang, S., Qiu, X., Xie, W., Yin, W., Wang, C., Su, D., Zhu, Y., Xu, R., & Li, J. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05127
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.